Program
Iron
Also written as “PA21”, “PA21 (2.5 g tablet containing 500 mg iron)” and “CTX001 With Iron”.
Its studies are mostly in Hyperphosphatemia · Anemia · Renal Insufficiency, Chronic · Colorectal Neoplasms, led by 4 companies.
Drug pageIron: every studyAll 86 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSLits history only | 100 open or running | phase 3since Mar 24, 2011 | Jan 9, 2009 | none ahead |
| Kissei Pharmaceuticalits history only | 50 open or running | phase 3since Apr 12, 2013 | Jan 26, 2012 | none ahead |
| Cajal Therapeutics | 11 open or running | early phase 1since May 5, 2026 | May 5, 2026 | none ahead |
| J. Uriachits history only | 10 open or running | phase 4since Sep 16, 2005 | Sep 16, 2005 | none ahead |
Also a collaborator on its studies: Fresenius Medical Care.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Cajal Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 5, 2026First study: early phase 1 study in AnemiaFirst studyNCT07577817 · 72 planned · Australia
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Cajal Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07577817Anemia · Australia | Early 1 | Recruiting | Oct 2026 | 72 |
How it is read
Names in the registry
- “PA21”, 11 entries
- “PA21 (2.5 g tablet containing 500 mg iron)”, 2 entries
- “CTX001 With Iron”, 1 entry
- “IV iron”, 1 entry
- “1.25 g PA21 (250 mg iron)”, 1 entry
Codes read as this program: PA21.
Conditions, from the studies’ own filings
- Hyperphosphatemia, 6 studies
- Anemia, 2 studies
- Renal Insufficiency, Chronic, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.